一种新的抗体疗法显示,在实验室和动物测试中,对攻击性、难以治疗的乳腺癌有希望。 A new antibody therapy shows promise against aggressive, hard-to-treat breast cancers in lab and animal tests.

伦敦国王学院开发的一种新的“三重工程”抗体在治疗侵袭性、难治性乳腺癌方面显示出前景，包括影响约 15% 的患者且缺乏共同治疗靶点的三阴性乳腺癌。 A new "triple-engineered" antibody developed by King’s College London shows promise in treating aggressive, treatment-resistant breast cancers, including triple-negative breast cancer, which affects about 15% of patients and lacks common treatment targets. 在实验室和动物研究中,治疗与肿瘤和血液中的癌症细胞和活性免疫细胞有效结合,克服了免疫抑制,并大大减缓了肿瘤的生长。 In lab and animal studies, the therapy effectively bound to cancer cells and activated immune cells both within tumors and in the bloodstream, overcoming immune suppression and significantly slowing tumor growth. 研究人员说,这一方法可以为选择有限的病人,特别是受三联阴性乳腺癌影响较大的年轻妇女和黑人妇女,提供一大进步。 Researchers say the approach could offer a major advance for patients with limited options, especially younger women and Black women disproportionately affected by triple-negative breast cancer. 治疗仍处于实验阶段,临床试验尚待进行,但由于共同的分子目标,还可能适用于卵巢癌和子宫内癌。 The therapy is still experimental, with clinical trials pending, but may also apply to ovarian and endometrial cancers due to shared molecular targets.